Genmab A/S ADS (GMAB) Stock: Buy, Sell, or Hold?
GMAB - Genmab A/S ADS
$34.75
0.20 (0.58%)
â˛
5d:
-1.61%
30d:
+1.56%
90d:
+24.06%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When GMAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: GMAB is fairly priced but lacks strong directional signals. At 9.3% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: GMAB is fairly priced but lacks strong directional signals. At 9.3% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$51.84
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$32.19
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMAB is currently trading at $34.75, which is considered slightly high relative to its 30-day fair value range of $33.19 to $35.06. From a valuation perspective, the stock is trading at a premium (Forward PE: 22.7) compared to its historical average (17.4). At these levels, the market is pricing in 9.3% annual earnings growth.
Technical Outlook: Technically, GMAB is in a strong uptrend. Immediate support is located at $33.22, while resistance sits at $35.91.
Market Sentiment: GMAB scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $39.05 (+12.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GMAB is in a strong uptrend. Immediate support is located at $33.22, while resistance sits at $35.91.
Market Sentiment: GMAB scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $39.05 (+12.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$33.19 -
$35.06
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
43.8%
All Signals
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($39.05)
- BULLISH: Expecting earnings turnaround to 9.3% growth with 24.9% revenue growth
- WARNING: Composite score 47/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$33.19 -
$35.06
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$33.22
Resistance Level
$35.91
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.71
Wall Street Target
$39.05
(+12.4%)
Revenue Growth (YoY)
24.9%
Earnings Growth (YoY)
-9.4%
Profit Margin
19.1%
Valuation Premium vs History
+9.3% premium
PE vs Historical
22.7 vs 17.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+9.3%
(market-implied from PE analysis)
1-Year Target
$37.98
(+9%)
2-Year Target
$41.51
(+20%)
3-Year Target
$45.37
(+31%)
3-Yr Target (if PE normalizes)
(PE: 23â17)
PE COMPRESSION
$34.76
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.7, Growth: 29.7%)
$75.75
(+118%)
Base:
(SPY PE: 20.4, Growth: 29.7%)
$68.04
(+96%)
Bear:
(PE: 17.3, Growth: 29.7%)
$57.83
(+66%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (27x PE), but valuation improves significantly next year (23x PE) as earnings recover.
Trailing PE: 27.20 | Current EPS (TTM): $1.27
Bull Case
$45.79
(+32%)
Analyst growth 20.5%, PE expands to 29.9
Base Case
$41.62
(+20%)
Market implied 20.5%, PE stable at 27.2
Bear Case
$23.49
(-32%)
Severe decline -20.0%, PE contracts to 23.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 03, 2026 11:52 PM ET
Data refreshes hourly during market hours. Next update: 12:51 AM
Data refreshes hourly during market hours. Next update: 12:51 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 63 BUY |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$21 | 50 HOLD |
